Cullinan Therapeutics, Inc.
CGEMNASDAQHealthcare● Active
$13.28
$-0.23(-1.70%)
Market Cap$816162240
P/E Ratio—
52W High$16.74
52W Low$5.68
Cullinan Therapeutics, Inc. (CGEM) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CGEM · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.02B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | ($0.00B) | $0.00B | $0.00B | $0.02B |
| Gross Margin %(computed) | — | — | — | — | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $0.19B | $0.14B | $0.15B | $0.09B | $0.06B |
| G&A Expenses | $0.05B | $0.05B | $0.04B | $0.04B | $0.03B |
| Total Operating Expenses | $0.24B | $0.20B | $0.19B | ($0.14B) | $0.09B |
| Operating Income | ($0.24B) | ($0.20B) | ($0.19B) | $0.14B | ($0.07B) |
| Operating Margin %(computed) | — | — | — | — | -358.73% |
| Interest Income | $0.02B | $0.03B | $0.02B | $0.01B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.22B) | ($0.17B) | ($0.17B) | $0.15B | ($0.07B) |
| Income Tax Expense | $0.00B | $0.00B | ($0.01B) | $0.04B | $0.00B |
| Net Income | ($0.22B) | ($0.17B) | ($0.15B) | $0.11B | ($0.07B) |
| Net Margin %(computed) | — | — | — | — | -346.14% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.72 | $-3.11 | $-3.69 | $2.46 | $-1.48 |
| Wtd Avg Shares | 0.06B | 0.05B | 0.04B | 0.05B | 0.04B |
| EBITDA | ($0.24B) | ($0.17B) | ($0.19B) | ($0.13B) | ($0.07B) |
| EBITDA Margin %(computed) | — | — | — | — | -358.45% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Cullinan Therapeutics, Inc. data
About Cullinan Therapeutics, Inc. (CGEM) Income Statement
Cullinan Therapeutics, Inc. (CGEM) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CGEM reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.22B) — a net profit margin of —.
Frequently asked questions
CGEM · 4 questionsCullinan Therapeutics, Inc. (CGEM) reported revenue of $0.00B for 2025, down —% year-over-year.
CGEM revenueCGEM salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08